Table 2.
Top mimic or reverse drugs for selected perturbation groups. Enriched drugs with nominal targets and overlap scores were found using the LINCSL1000 CDS database for the t-SNE perturbation group consensus signatures. The enriched drugs act as inhibitors of the indicated targets unless otherwise stated
| In vitro group | Broad annotation | Top mimic drugs | Target | Score |
|---|---|---|---|---|
| 6 | Cytokine | Ingenol 3, 20-dibenzoate | PKC activator | 0.0534 |
| 33 | HDAC inhibition | Vorinostat | HDACs | 0.0933 |
|
| ||||
| Disease Group | Top reverse drugs | Nominal target | Score | |
|
| ||||
| 8 | RA | Curcubitacin I | JAK/STAT3 | 0.0389 |
| 15d-PGJ2 | PPARG activator | 0.0354 | ||
| Bortezomib | Proteasome | 0.0349 | ||
| 11 | Osteoarthritis | Narciclasine | Apoptosis | 0.0659 |
| Manumycin A | Ras | 0.0579 | ||
| Salermide | SIRT1/2 | 0.0568 | ||
| 35 | Animal models Osteoarthritis | Selumetinib | MEK1/2 | 0.0574 |
| TG101348 | PI3K | 0.0549 | ||
| BMS-536924 | IGF1R | 0.0544 | ||